Structured Review

Boehringer Ingelheim igg isotype control antibody
Combined treatment of IGF blocking antibody with <t>paclitaxel</t> decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control <t>IgG</t> antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test
Igg Isotype Control Antibody, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg isotype control antibody/product/Boehringer Ingelheim
Average 92 stars, based on 2 article reviews
Price from $9.99 to $1999.99
igg isotype control antibody - by Bioz Stars, 2020-08
92/100 stars

Images

1) Product Images from "Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer"

Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

Journal: Oncogene

doi: 10.1038/s41388-017-0115-x

Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test
Figure Legend Snippet: Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

Techniques Used: Blocking Assay, Luciferase, Mouse Assay, Immunohistochemistry, Staining

Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel
Figure Legend Snippet: Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

Techniques Used: Blocking Assay, Luciferase, Mouse Assay, Staining, Software, Derivative Assay

2) Product Images from "Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer"

Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

Journal: Oncogene

doi: 10.1038/s41388-017-0115-x

Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test
Figure Legend Snippet: Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

Techniques Used: Blocking Assay, Luciferase, Mouse Assay, Immunohistochemistry, Staining

Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel
Figure Legend Snippet: Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

Techniques Used: Blocking Assay, Luciferase, Mouse Assay, Staining, Software, Derivative Assay

Related Articles

Blocking Assay:

Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer
Article Snippet: .. Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days. .. At humane endpoint, primary tumors and lungs were harvested, imaged using IVIS technology and tissues were either digested for FACS sorting and analysis (see details below) or formalin-fixed and paraffin-embedded.

Mouse Assay:

Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer
Article Snippet: .. Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days. .. At humane endpoint, primary tumors and lungs were harvested, imaged using IVIS technology and tissues were either digested for FACS sorting and analysis (see details below) or formalin-fixed and paraffin-embedded.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85
    Boehringer Ingelheim immunoglobulin g isotypes
    Linear BPI epitopes recognized by BPI–ANCA <t>IgG</t> of TAP-deficient patients. Binding of patients’ IgG to cellulose-bound peptides was performed as described in Methods. Numbering of amino acid sequence is according to the sequence of rBPI published by Beamer et al ]. Shown are residues 1–456. Regions recognized by IgG from BPI–ANCA positive patients’ and goat anti-BPI antiserum are shown as horizontal bars. Regions that retain endotoxin neutralizing and antibiotic activity are shown in bold italics.
    Immunoglobulin G Isotypes, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunoglobulin g isotypes/product/Boehringer Ingelheim
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    immunoglobulin g isotypes - by Bioz Stars, 2020-08
    85/100 stars
      Buy from Supplier

    92
    Boehringer Ingelheim igg isotype control antibody
    Combined treatment of IGF blocking antibody with <t>paclitaxel</t> decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control <t>IgG</t> antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test
    Igg Isotype Control Antibody, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igg isotype control antibody/product/Boehringer Ingelheim
    Average 92 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    igg isotype control antibody - by Bioz Stars, 2020-08
    92/100 stars
      Buy from Supplier

    Image Search Results


    Linear BPI epitopes recognized by BPI–ANCA IgG of TAP-deficient patients. Binding of patients’ IgG to cellulose-bound peptides was performed as described in Methods. Numbering of amino acid sequence is according to the sequence of rBPI published by Beamer et al ]. Shown are residues 1–456. Regions recognized by IgG from BPI–ANCA positive patients’ and goat anti-BPI antiserum are shown as horizontal bars. Regions that retain endotoxin neutralizing and antibiotic activity are shown in bold italics.

    Journal: Clinical and Experimental Immunology

    Article Title: BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections

    doi: 10.1046/j.1365-2249.2003.02197.x

    Figure Lengend Snippet: Linear BPI epitopes recognized by BPI–ANCA IgG of TAP-deficient patients. Binding of patients’ IgG to cellulose-bound peptides was performed as described in Methods. Numbering of amino acid sequence is according to the sequence of rBPI published by Beamer et al ]. Shown are residues 1–456. Regions recognized by IgG from BPI–ANCA positive patients’ and goat anti-BPI antiserum are shown as horizontal bars. Regions that retain endotoxin neutralizing and antibiotic activity are shown in bold italics.

    Article Snippet: Immunoglobulin G isotypes were determined using anti-IgG1–IgG4 antibodies (Boehringer, Ingelheim, Germany).

    Techniques: Binding Assay, Sequencing, Activity Assay

    Antibacterial activity of rBPI and rBPI 21 against E. coli DH5α is inhibited by patients’ BPI–ANCA in vitro . Effects of purified IgG preparations from BPI–ANCA-positive patients in a constant concentration of 250 µg/ml on the antibiotic activity of rBPI (a) and rBPI 21 (b) against E. coli DH5α were measured as described in Methods. Pooled human IgG served as negative control, purified IgG from goat anti-BPI antiserum served as positive control. The results shown represent the mean of at least three experiments. For clarity, error bars have been left out; variation was

    Journal: Clinical and Experimental Immunology

    Article Title: BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections

    doi: 10.1046/j.1365-2249.2003.02197.x

    Figure Lengend Snippet: Antibacterial activity of rBPI and rBPI 21 against E. coli DH5α is inhibited by patients’ BPI–ANCA in vitro . Effects of purified IgG preparations from BPI–ANCA-positive patients in a constant concentration of 250 µg/ml on the antibiotic activity of rBPI (a) and rBPI 21 (b) against E. coli DH5α were measured as described in Methods. Pooled human IgG served as negative control, purified IgG from goat anti-BPI antiserum served as positive control. The results shown represent the mean of at least three experiments. For clarity, error bars have been left out; variation was

    Article Snippet: Immunoglobulin G isotypes were determined using anti-IgG1–IgG4 antibodies (Boehringer, Ingelheim, Germany).

    Techniques: Activity Assay, In Vitro, Purification, Concentration Assay, Negative Control, Positive Control

    Inhibition of antibacterial activity of rBPI 21 against E.coli DH5α by BPI–ANCA IgG can be reversed by preabsorption on rBPI 21 . Preabsorption of BPI–ANCA IgG from patient 2 was performed using either an rBPI 21 coated (8 µg/ml), an E.coli DH5α coated (heat-inactivated, 10 6 /ml) or an uncoated ELISA plate prior to use in the growth inhibition assay. Results show the mean of two experiments.

    Journal: Clinical and Experimental Immunology

    Article Title: BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections

    doi: 10.1046/j.1365-2249.2003.02197.x

    Figure Lengend Snippet: Inhibition of antibacterial activity of rBPI 21 against E.coli DH5α by BPI–ANCA IgG can be reversed by preabsorption on rBPI 21 . Preabsorption of BPI–ANCA IgG from patient 2 was performed using either an rBPI 21 coated (8 µg/ml), an E.coli DH5α coated (heat-inactivated, 10 6 /ml) or an uncoated ELISA plate prior to use in the growth inhibition assay. Results show the mean of two experiments.

    Article Snippet: Immunoglobulin G isotypes were determined using anti-IgG1–IgG4 antibodies (Boehringer, Ingelheim, Germany).

    Techniques: Inhibition, Activity Assay, Enzyme-linked Immunosorbent Assay, Growth Inhibition Assay

    Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Immunohistochemistry, Staining

    Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Staining, Software, Derivative Assay

    Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Immunohistochemistry, Staining

    Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Staining, Software, Derivative Assay